The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.
- Published In:
- Journal of diabetes, 17(8), e70119 (2025)
- Authors:
- Wen, Jimmy(4), Ansari, Ubaid, Shehabat, Mouhamad, Ansari, Zaid, Syed, Burhaan, Razick, Adam, Razick, Daniel, Akhtar, Muzammil, Frezza, Eldo
- Database ID:
- RPEP-14126
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14126APA
Wen, Jimmy; Ansari, Ubaid; Shehabat, Mouhamad; Ansari, Zaid; Syed, Burhaan; Razick, Adam; Razick, Daniel; Akhtar, Muzammil; Frezza, Eldo. (2025). The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.. Journal of diabetes, 17(8), e70119. https://doi.org/10.1111/1753-0407.70119
MLA
Wen, Jimmy, et al. "The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.." Journal of diabetes, 2025. https://doi.org/10.1111/1753-0407.70119
RethinkPeptides
RethinkPeptides Research Database. "The Potential of SARMs and Antimyostatin Agents in Addressin..." RPEP-14126. Retrieved from https://rethinkpeptides.com/research/wen-2025-the-potential-of-sarms
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.